Tessa Romero
Stock Analyst at JP Morgan
(4.27)
# 357
Out of 5,182 analysts
83
Total ratings
50%
Success rate
19.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tessa Romero
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AGIO Agios Pharmaceuticals | Maintains: Neutral | $31 → $36 | $28.16 | +27.84% | 9 | Apr 6, 2026 | |
| SEPN Septerna | Maintains: Overweight | $34 → $38 | $23.61 | +60.95% | 1 | Mar 24, 2026 | |
| EWTX Edgewise Therapeutics | Maintains: Overweight | $34 → $45 | $30.61 | +47.01% | 12 | Mar 17, 2026 | |
| CYTK Cytokinetics | Maintains: Overweight | $74 → $75 | $63.35 | +18.39% | 7 | Mar 17, 2026 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $47 → $50 | $46.37 | +7.84% | 7 | Mar 16, 2026 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Overweight | $31 → $34 | $21.95 | +54.90% | 12 | Mar 4, 2026 | |
| DYN Dyne Therapeutics | Maintains: Neutral | $17 → $16 | $17.39 | -7.99% | 8 | Jan 20, 2026 | |
| XENE Xenon Pharmaceuticals | Maintains: Overweight | $60 → $62 | $56.13 | +10.46% | 4 | Jan 9, 2026 | |
| OCS Oculis Holding AG | Initiates: Overweight | $38 | $27.48 | +38.28% | 1 | Dec 19, 2025 | |
| BHVN Biohaven | Maintains: Overweight | $47 → $15 | $9.63 | +55.76% | 8 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $261 → $263 | $3.56 | +7,287.64% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $2.44 | - | 5 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $10 | $5.77 | +73.31% | 2 | May 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $9.40 | +304.26% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $7.61 | - | 2 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $29 | $13.34 | +117.39% | 3 | Aug 13, 2024 |
Agios Pharmaceuticals
Apr 6, 2026
Maintains: Neutral
Price Target: $31 → $36
Current: $28.16
Upside: +27.84%
Septerna
Mar 24, 2026
Maintains: Overweight
Price Target: $34 → $38
Current: $23.61
Upside: +60.95%
Edgewise Therapeutics
Mar 17, 2026
Maintains: Overweight
Price Target: $34 → $45
Current: $30.61
Upside: +47.01%
Cytokinetics
Mar 17, 2026
Maintains: Overweight
Price Target: $74 → $75
Current: $63.35
Upside: +18.39%
Scholar Rock Holding
Mar 16, 2026
Maintains: Overweight
Price Target: $47 → $50
Current: $46.37
Upside: +7.84%
ACADIA Pharmaceuticals
Mar 4, 2026
Maintains: Overweight
Price Target: $31 → $34
Current: $21.95
Upside: +54.90%
Dyne Therapeutics
Jan 20, 2026
Maintains: Neutral
Price Target: $17 → $16
Current: $17.39
Upside: -7.99%
Xenon Pharmaceuticals
Jan 9, 2026
Maintains: Overweight
Price Target: $60 → $62
Current: $56.13
Upside: +10.46%
Oculis Holding AG
Dec 19, 2025
Initiates: Overweight
Price Target: $38
Current: $27.48
Upside: +38.28%
Biohaven
Nov 20, 2025
Maintains: Overweight
Price Target: $47 → $15
Current: $9.63
Upside: +55.76%
Nov 18, 2025
Downgrades: Underweight
Price Target: $261 → $263
Current: $3.56
Upside: +7,287.64%
Sep 16, 2025
Downgrades: Underweight
Price Target: n/a
Current: $2.44
Upside: -
May 30, 2025
Maintains: Overweight
Price Target: $16 → $10
Current: $5.77
Upside: +73.31%
Nov 5, 2024
Initiates: Overweight
Price Target: $38
Current: $9.40
Upside: +304.26%
Oct 24, 2024
Downgrades: Underweight
Price Target: n/a
Current: $7.61
Upside: -
Aug 13, 2024
Maintains: Overweight
Price Target: $32 → $29
Current: $13.34
Upside: +117.39%